DK2912021T3 - Aggrecanase-hæmmere - Google Patents
Aggrecanase-hæmmere Download PDFInfo
- Publication number
- DK2912021T3 DK2912021T3 DK13785745.4T DK13785745T DK2912021T3 DK 2912021 T3 DK2912021 T3 DK 2912021T3 DK 13785745 T DK13785745 T DK 13785745T DK 2912021 T3 DK2912021 T3 DK 2912021T3
- Authority
- DK
- Denmark
- Prior art keywords
- formula
- pharmaceutically acceptable
- compound
- acceptable salt
- compound according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
- C07D233/78—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (11)
1. Forbindelse med formlen:
Formel I hvor R-ι er udvalgt blandt methyl, ethyl, propyl, dimethyl og cyclopropyl, eller et farmaceutisk acceptabelt salt deraf.
2. Forbindelse ifølge krav 1 med formlen:
Formel la; eller et farmaceutisk acceptabelt salt deraf.
3. Forbindelse ifølge krav 1 med formlen:
Formel Ib;
Formel Id;
Formel If;
Formel Ih;
Formel Ij; eller
Formel II; eller et farmaceutisk acceptabelt salt deraf.
4. Forbindelse ifølge krav 3 med formlen:
Formel le;
Formel lg;
Formel li;
Formel Ik; eller
Formel Im; eller et farmaceutisk acceptabelt salt deraf.
5. Forbindelse ifølge krav 1 med formlen:
Formel le eller et farmaceutisk acceptabelt salt deraf.
6. Farmaceutisk sammensætning omfattende en forbindelse ifølge et af kravene 1 til 5, eller et farmaceutisk acceptabelt salt deraf, og mindst en af en farmaceutisk acceptabel bærer, hjælpestof eller fortyndingsmiddel.
7. Farmaceutisk sammensætning ifølge krav 6, hvor den farmaceutiske sammensætning er tilpasset til oral indgivelse.
8. Farmaceutisk sammensætning ifølge krav 6 eller krav 7, hvor den farmaceutiske sammensætning er i form af en tablet, kapsel, opløsning eller suspension.
9. Forbindelse ifølge et af kravene 1 til 5, eller et farmaceutisk acceptabelt salt deraf, til anvendelse inden for terapi.
10. Forbindelse ifølge et af kravene 1 til 5, eller et farmaceutisk acceptabelt salt deraf, til anvendelse ved behandling af arthritis.
11. Forbindelse ifølge et af kravene 1 til 5, eller et farmaceutisk acceptabelt salt deraf, til anvendelse ved hæmning af brusk-erosion.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718965P | 2012-10-26 | 2012-10-26 | |
| PCT/US2013/065591 WO2014066151A1 (en) | 2012-10-26 | 2013-10-18 | Aggrecanase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2912021T3 true DK2912021T3 (da) | 2017-10-02 |
Family
ID=49515523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13785745.4T DK2912021T3 (da) | 2012-10-26 | 2013-10-18 | Aggrecanase-hæmmere |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9206139B2 (da) |
| EP (1) | EP2912021B1 (da) |
| JP (1) | JP6251279B2 (da) |
| KR (1) | KR101689983B1 (da) |
| CN (1) | CN104755464B (da) |
| AR (1) | AR092971A1 (da) |
| AU (1) | AU2013334989B2 (da) |
| BR (1) | BR112015009032B1 (da) |
| CA (1) | CA2886526C (da) |
| DK (1) | DK2912021T3 (da) |
| EA (1) | EA026037B1 (da) |
| ES (1) | ES2645970T3 (da) |
| HK (1) | HK1211927A1 (da) |
| HU (1) | HUE034616T2 (da) |
| MX (1) | MX364207B (da) |
| NZ (1) | NZ706772A (da) |
| PL (1) | PL2912021T3 (da) |
| PT (1) | PT2912021T (da) |
| TW (1) | TWI620738B (da) |
| WO (1) | WO2014066151A1 (da) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2739948T3 (es) | 2014-10-16 | 2020-02-04 | Monsanto Technology Llc | Proteínas variantes con secuencias de aminoácidos Cry1Da1 activas contra lepidópteros |
| JO3501B1 (ar) * | 2014-12-22 | 2020-07-05 | Servier Lab | مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام) |
| GB201610056D0 (en) | 2016-06-09 | 2016-07-27 | Galapagos Nv And Laboratoires Servier Les | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis |
| GB201610055D0 (en) * | 2016-06-09 | 2016-07-27 | Galapagos Nv And Laboratoires Servier Les | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis |
| WO2021011720A2 (en) * | 2019-07-18 | 2021-01-21 | Avidence Therapeutics, Inc. | Anti-osteoarthritis compounds and related compositions and methods |
| EP3822265A1 (en) | 2019-11-15 | 2021-05-19 | Bayer AG | Substituted hydantoinamides as adamts7 antagonists |
| EP3822268A1 (en) | 2019-11-15 | 2021-05-19 | Bayer Aktiengesellschaft | Substituted hydantoinamides as adamts7 antagonists |
| WO2021214637A1 (en) * | 2020-04-20 | 2021-10-28 | St. Jude Children's Research Hospital | Composition and methods for treating respiratory diseases |
| WO2022007866A1 (zh) * | 2020-07-09 | 2022-01-13 | 深圳信立泰药业股份有限公司 | 并三环类衍生物、其制备方法及其在医药上的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2333412T3 (es) * | 2001-05-25 | 2010-02-22 | Bristol-Myers Squibb Company | Derivados de hidantoina como inhibidores de metaloproteinasas de matriz. |
| SE0202539D0 (sv) * | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
| CA2612585A1 (en) * | 2005-06-27 | 2007-01-04 | Amgen Inc. | Anti-inflammatory aryl nitrile compounds |
| TW200800209A (en) * | 2005-07-11 | 2008-01-01 | Wyeth Corp | Glutamate aggrecanase inhibitors |
| AR059037A1 (es) * | 2006-01-17 | 2008-03-12 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
| TW200831488A (en) * | 2006-11-29 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
-
2013
- 2013-10-10 AR ARP130103679A patent/AR092971A1/es active IP Right Grant
- 2013-10-15 TW TW102137198A patent/TWI620738B/zh active
- 2013-10-18 ES ES13785745.4T patent/ES2645970T3/es active Active
- 2013-10-18 DK DK13785745.4T patent/DK2912021T3/da active
- 2013-10-18 NZ NZ706772A patent/NZ706772A/en unknown
- 2013-10-18 HU HUE13785745A patent/HUE034616T2/en unknown
- 2013-10-18 JP JP2015539672A patent/JP6251279B2/ja active Active
- 2013-10-18 EA EA201590621A patent/EA026037B1/ru not_active IP Right Cessation
- 2013-10-18 KR KR1020157010390A patent/KR101689983B1/ko active IP Right Grant
- 2013-10-18 EP EP13785745.4A patent/EP2912021B1/en active Active
- 2013-10-18 WO PCT/US2013/065591 patent/WO2014066151A1/en active Application Filing
- 2013-10-18 CA CA2886526A patent/CA2886526C/en active Active
- 2013-10-18 US US14/422,018 patent/US9206139B2/en active Active
- 2013-10-18 MX MX2015005297A patent/MX364207B/es active IP Right Grant
- 2013-10-18 PL PL13785745T patent/PL2912021T3/pl unknown
- 2013-10-18 AU AU2013334989A patent/AU2013334989B2/en active Active
- 2013-10-18 CN CN201380055719.9A patent/CN104755464B/zh active Active
- 2013-10-18 PT PT137857454T patent/PT2912021T/pt unknown
- 2013-10-18 BR BR112015009032-0A patent/BR112015009032B1/pt active IP Right Grant
-
2015
- 2015-12-28 HK HK15112729.6A patent/HK1211927A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201427955A (zh) | 2014-07-16 |
| AR092971A1 (es) | 2015-05-06 |
| US20150218107A1 (en) | 2015-08-06 |
| EA201590621A1 (ru) | 2015-07-30 |
| US9206139B2 (en) | 2015-12-08 |
| KR20150058480A (ko) | 2015-05-28 |
| CA2886526C (en) | 2018-03-27 |
| MX2015005297A (es) | 2015-07-17 |
| WO2014066151A1 (en) | 2014-05-01 |
| PT2912021T (pt) | 2017-11-14 |
| AU2013334989B2 (en) | 2016-02-18 |
| EP2912021B1 (en) | 2017-08-16 |
| BR112015009032B1 (pt) | 2022-06-28 |
| TWI620738B (zh) | 2018-04-11 |
| EP2912021A1 (en) | 2015-09-02 |
| BR112015009032A2 (pt) | 2017-07-04 |
| JP2015535248A (ja) | 2015-12-10 |
| KR101689983B1 (ko) | 2016-12-26 |
| CA2886526A1 (en) | 2014-05-01 |
| HUE034616T2 (en) | 2018-02-28 |
| CN104755464B (zh) | 2017-03-29 |
| AU2013334989A1 (en) | 2015-04-23 |
| HK1211927A1 (en) | 2016-06-03 |
| EA026037B1 (ru) | 2017-02-28 |
| ES2645970T3 (es) | 2017-12-11 |
| PL2912021T3 (pl) | 2018-01-31 |
| NZ706772A (en) | 2018-05-25 |
| MX364207B (es) | 2019-04-16 |
| CN104755464A (zh) | 2015-07-01 |
| JP6251279B2 (ja) | 2017-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2912021T3 (da) | Aggrecanase-hæmmere | |
| US8664388B2 (en) | Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture | |
| Leonhardt et al. | Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors | |
| Cherney et al. | Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-α converting enzyme inhibitors | |
| US8426607B2 (en) | Substituted amino-benzimidazoles, medicaments comprimising said compound, their use and their method of manufacture | |
| EP2714679A1 (en) | Novel imidazole derivatives useful for the treatment of arthritis | |
| Nakahara et al. | Discovery of potent and centrally active 6-substituted 5-fluoro-1, 3-dihydro-oxazine β-secretase (BACE1) inhibitors via active conformation stabilization | |
| EP0821675A1 (en) | Novel hydroxamic acid and amino-carboxylate compounds as metalloprotease and tnf inhibitors | |
| FI113965B (fi) | 8-okso-4-oksa-1,7-diatsatrisyklo-oktadekatetraen-9-yylikarbamoyylijohdannaiset matriisimetalloproteaasi-inhibiittoreina | |
| G Li et al. | Discovery of selective small molecular TACE inhibitors for the treatment of rheumatoid arthritis | |
| RU2802426C2 (ru) | Ингибиторы белка активации фибробластов | |
| WO2024033293A1 (en) | Difluoro- and trifluoro-acetyl hydrazides as selective hdac6 inhibitors | |
| US20240228460A1 (en) | Protease inhibitors and methods of making same | |
| JP2005023007A (ja) | 複素環化合物およびその用途 |